期刊文献+

不同剂量阿托伐他汀降脂效果与对颈动脉粥样斑块影响的观察 被引量:2

The effect of different dose of atorvastatin on arteriosclerosis plaque of carotid artery and lipid-lowering
下载PDF
导出
摘要 目的:探讨不同剂量阿托伐他汀对高脂血症患者颈动脉粥样斑块的消退作用及降脂疗效。方法:选用高脂血症伴颈动脉粥样斑块患者219例,按阿托伐他汀用药剂量不同分为3组:20mg组75例、10mg组71例和对照组73例,观察治疗6个月后Tc、TG、LDL-c及颈动脉斑块的变化。结果:①阿托伐他汀在改善血脂方面优于对照组(P<0.05或P<0.01),20mg组优于10mg组(P<0.05);②阿托伐他汀在治疗颈动脉粥样斑块方面明显优于对照组,20mg组优于对照组(P<0.05),20mg组优于10mg组(P<0.05)。结论:较大剂量阿托伐他汀可明显缩小颈动脉粥样斑块,有效降低血脂,从而降低心脑血管事件的发生,无明显不良反应。 Objective:To study the effect of different dose of atorvastatin on arteriosclerosis plaque of carotid artery and lipid-lowering in hyperlipidemic patients.Methods:219 patients with hyperlipidemic and atherosclerosis were divided into three groups.Respectively received atorvastatin 20mg qd(n=75) and 10mg qd(n=71) and no atorvastatin(n=73) for 6 months.The levels of TC,TG,LDL-C were detected.Color Dpppler echocardiography was used to measure intima-media thickness (ITM) of the common carotid artery.Results:①The effect of lipid-lowering in received atorvastatin group was better than no receive(P〈0.05或P〈0.01),20mg/d group was better than 10mg/d group(P〈0.05);②For reduced the arteriosclerosis plaque of carotid artery,20mg/d group was better than 10mg/d group(P〈0.05),20mg/d group was better than no receive group(P〈0.05).Conclusion:High-dose atorvastatin treatment can effectly reduced the arteriosclerosis plaque of carotid artery and hyperlipidemia.
作者 戴立华
出处 《医学信息(中旬刊)》 2010年第10期2926-2927,共2页 Medical Information Operations Sciences Fascicule
关键词 阿托伐他汀 颈动脉 IMT 脂类 Atorvastatin Carotid artery IMT Lipid
  • 相关文献

参考文献6

二级参考文献15

  • 1Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension, 2002, 40:687-693.
  • 2Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vivo and in vitro by peroxisome proliferators-activator-γ activators. Circulation, 2000,101:235-238.
  • 3Libby P. Current concepts of the pathogenesis of the acute coronary syndrome. Circulation, 2001, 104: 365-372.
  • 4Jovinge S, Ares MP, Kallin J, et al. Human monocytes/macrophages release TNF-alpha in responsible to OxLDL. Atherioscler Thromb Vasc Biol, 1996, 16: 1573-1579.
  • 5The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994,344:1383-1389.
  • 6Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atheroslerosis in apolipoprotein E-Knockout mice. Circulation, 2002, 106: 2700-2706.
  • 7Brown DL, Hibbs MS, Kearney M,et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation, 1995, 91:2125-2131.
  • 8Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res, 2002, 91:852-859.
  • 9Baker AH, Edwards DR, Murphy G,et al. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci, 2002, 115:3719-3727.
  • 10Zelvyte I, Dominatiene R, Crisby M, et al. Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in responsible to lipoproteins in human monocytes in vitro. Parmacol Res, 2002, 45: 147-154.

共引文献1235

同被引文献23

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部